Proton therapy combined with concurrent chemotherapy achieves a 43.7% five-year overall survival rate for patients with unresectable stage III non-small cell lung cancer, according to a Japanese national registry study published in Radiotherapy and Oncology. The findings offer new data on long-term outcomes for advanced lung cancer treatments that spare surrounding healthy tissues.
Proton Therapy Outcomes in Unresectable Stage III Lung Cancer
Between May 2016 and June 2020, researchers evaluated 156 patients treated with concurrent chemotherapy and proton therapy across 12 proton therapy centers. Patients received radiation doses ranging from 60 to 74 Gy relative biological effectiveness over 30 to 37 fractions. Following chemoradiotherapy, 42.3% of patients received consolidation immunotherapy with durvalumab.
The study group included challenging patient profiles. Ten patients had interstitial pneumonia, and 31 patients were deemed unsuitable for definitive photon-based chemoradiotherapy due to organ-at-risk dose constraints. After a median follow-up of 49 months among survivors, overall survival reached 72.9% at two years and 43.7% at five years, with a median overall survival of 45 months. Progression-free survival was 35.4% at two years and 21.3% at five years.
Treatment-related toxicity remained manageable within the cohort. Grade 2 radiation pneumonitis occurred in 19.9% of patients, while grade 3 pneumonitis affected 3.2%. No grade 4 or higher toxicities or treatment-related deaths occurred. Among the 31 patients considered unsuitable for photon therapy, two-year overall survival was 58.1%, and five-year overall survival was 27.5%.
PACIFIC-R Pneumonitis Risk Factors After Durvalumab
Symptomatic pneumonitis presents a significant risk for patients receiving consolidation durvalumab after chemoradiotherapy. An analysis from the international PACIFIC-R study, published in Clinical and Translational Radiation Oncology, examined 268 patients to identify factors associated with lung inflammation.
During durvalumab treatment, 19.4% of patients developed symptomatic pneumonitis of grade 2 or higher, or required corticosteroid treatment. Multivariable analysis showed that a higher mean lung radiation dose significantly increased the odds of symptomatic pneumonitis, with an odds ratio of 4.73. Patients with a prior history of chronic obstructive pulmonary disease faced an odds ratio of 2.60.
Pneumonitis frequently disrupted treatment schedules. Of the 52 patients who developed symptomatic pneumonitis, only 10 finished the full course of durvalumab, while 31 stopped treatment due to adverse events.
ESTRO and EORTC Treatment Guidelines for Small Cell Lung Cancer
The European Society for Radiotherapy and Oncology and the European Organisation for Research and Treatment of Cancer published updated expert recommendations addressing stage I through stage III small cell lung cancer. The guidelines incorporate evidence available through January 2026, focusing on target delineation, dose schedules, and systemic therapy integration.
For eligible patients, standard thoracic radiotherapy remains 45 Gy delivered in 30 twice-daily fractions over three weeks, or an alternative schedule of 66 Gy in 33 once-daily fractions. The integration of consolidation durvalumab follows findings from the ADRIATIC trial, which demonstrated a median survival increase from 33.4 months with a placebo to 55.9 months with durvalumab.
Frequently Asked Questions About 2026 Lung Cancer Radiotherapy Advances
What role does consolidation immunotherapy play after proton chemoradiotherapy?
Consolidation immune checkpoint inhibitor therapy is associated with improved progression-free survival in multivariable analysis, though it also correlates with a higher risk of grade 2 or greater radiation pneumonitis.
How does pre-existing COPD affect lung cancer treatment safety?
Patients with a history of chronic obstructive pulmonary disease face an increased risk of developing symptomatic pneumonitis when receiving durvalumab following chemoradiotherapy, with an odds ratio of 2.60.
What are the standard radiation dose options for limited-stage small cell lung cancer?
Current European guidelines recommend either 45 Gy delivered in 30 twice-daily fractions over three weeks or 66 Gy in 33 once-daily fractions.
Related reading